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Abstract
Although vaccination against various pathogens is integral to health management of swine, vaccines against
parasites have not yet been commercialized for the use in pigs. The incentive to develop and commercialize
anti-parasitic vaccines in swine are twofold; on the one hand parasitic diseases which are economically important,
such as ascarosis and neonatal coccidiosis, could be controlled in a sustainable manner; on the other hand, the
transmission of zoonotic parasites, such as Toxoplasma gondii or Cysticercus cellulosae, could be effectively
interrupted. Although experimental research indicates that vaccination against a number of porcine parasites is
feasible, development and commercialization of potential vaccines so far has been very slow, as our knowledge on
the host-parasite interplay in porcine parasitic infections is still very limited. In the light of growing concerns
regarding consumer health and antiparasitic drug resistance, however, it is timely to re-direct R&D efforts to the
development of biological control options.
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Background - vaccines against parasites
In modern swine medicine, vaccination against various
pathogens is an integral part of the health management.
However, currently not a single vaccine against parasites
of swine is commercially available. Compared to viral and
bacterial pathogens, there is a general scarcity for anti-
parasite vaccines; only two anti-nematode vaccines, one
anti-tick-vaccine and a handful of antiprotozoal vaccines
are available for domestic animals. The reasons for such a
limited number of anti-parasite vaccines are manifold. For
many parasitic infections the development of immunity is
slow, and especially in livestock animals, the required time
is too short for the vaccine to be of value before animals
go to slaughter.
Since parasites, especially helminths, are prime manipu-
lators of the immune system, immunity is often also
incomplete and not sufficient to interrupt the life cycle,
which aids in the continuation of transmission in a popu-
lation regardless of vaccination. For host species with a
fast turnover the development of anti-parasite vaccines
are considered too expensive and especially in intensive
pig (or poultry) production chemical control is cheaper,
easier to apply and is considered to have a broader market.
The only anti-parasite vaccine currently available for use
in pigs, the anti-Cysticercus cellulosae-vaccine for the pre-
vention of porcine cysticercosis (which leads to infection
of humans with the tapeworm Taenia solium), is not yet
commercially available although it has a very good efficacy
[19]. Simplified and cost-effective application will have to
be developed to apply this highly effective vaccine to pigs
on a large scale, such as the expression of the recombinant
antigen in feed plants [28].
However, the development of vaccines against parasites is
still a significant research topic in medical and veterinary
sciences. Pathogenic and therefore economically important
diseases, especially those which are insufficiently controlled
by available chemotherapeutics or have developed resist-
ance against them that cannot be immediately overcome,
are still in the focus. In addition, zoonotic parasites repre-
sent an attractive target under the One Health aspect, and
finally there is a growing public interest in organic produc-
tion of food free of chemicals, which is fostered by con-
sumer concern about drug residues in meat, eggs or milk.
Which swine parasites are to be considered for vaccines?
The only group of vaccines against parasites that is well
developed are the anti-coccidial vaccines for poultry, i.e.
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Eimeria in chicken and turkey. Live virulent and attenu-
ated vaccines are the predominant types on the market;
some strains have been used for more than 50 year with-
out significant alterations [39]. Technically, vaccination
with life parasites, in this case Eimeria oocysts from
several relevant species, represents an infection of
susceptible animals under controlled conditions. The
parasites undergo the complete life cycle and recircula-
tion of oocysts induces a natural booster, rendering
chicken immune after several cycles of reproduction. It
is assumed that vaccine strains which are susceptible to
anticoccidials can displace resistant field isolates when
applied repeatedly [5].
In order to be a candidate for vaccine development, para-
sites have to fulfil several prerequisites. They must be suffi-
ciently pathogenic to induce disease and or/economic losses
that can be ameliorated by vaccination, and natural infec-
tions must be immunogenic and induce protective
immunity and an immunological memory. Amongst the
most common swine parasites, some fulfil these criteria.
Sarcoptes scabiei var. suis, the mange mite of pigs, causes se-
vere economic losses and frequently serious disease in pigs
when untreated [6]. Currently, control of porcine sarcoptic
mange relies on the application of acaricides and the main-
tenance of mite-free herds [18]. Immunity against scabies
has been described in different species including humans
[43]. Vaccination has been attempted in rodent models [11]
and other species, and it might also be feasible in pigs.
Strongyloides ransomi is a nematode which is most
commonly transmitted with the colostrum after reactiva-
tion of hypobiotic larvae in the sow. It causes transient
diarrhoea in suckling piglets and induces strong immunity
in the adult intestinal stage which leads to rapid expulsion
by the host. The immune mechanisms of expulsion have
been investigated for other Strongyloides species [51],
therefore this nematode also fulfils the principle criteria
for a vaccination candidate. This is also true for other
nematode species of swine that are expelled by action of
the gut immune system in pigs, the large roundworm,
Ascaris suum [24], and the whipworm, Trichuris suis. In
contrast to these the nodule worm Oesophagostomum
induces only a weak reaction of the host’s immune system
[1], making the latter unsuitable for immunological inter-
vention. With regard to the economic importance, porcine
nematodes, especially Strongyloides, Trichuris and the
nodule worms, have decreased in prevalence sind the
advent of broad-spectrum anthelminthics and modern
management, although A. suum prevalences can still be
considerable, especially in traditional management sys-
tems or on organic farms [16, 29–31].
Of the protozoa, Toxoplasma gondii is an attractive candi-
date for vaccine development, as it is the most important
foodborne zoonotic parasite on a global scale, and interrup-
tion of the life cycle by preventing cyst formation in animals
used for meat production would effectively truncate food-
borne transmission. A range of promising vaccine designs
and candidates has been used in mice [20], and also in pigs
(e.g. [3] for recent works). While it is assumed that vaccin-
ation of livestock against Toxoplasma can prevent infection
in humans, the infection in pigs causes only minor produc-
tion losses or animal health problems and the attractiveness
of such a vaccine for pig producers is certainly only limited
unless the label “Toxoplasma-free pork” has economic ad-
vantages. In suckling piglets Cystoisospora suis (syn. Isospora
suis) causes intestinal infections which may cause transient
diarrhoea mostly in the second week of life. Due to the pecu-
liarities of the porcine neonatal immune system (see below)
and the strong age resistance to C. suis in piglets older than
three weeks [46, 47], it is currently assumed that only pigs
older than six weeks can mount an appropriate immune re-
sponse. For this and other reasons vaccination of piglets
against C. suis is not considered feasible. However, alterna-
tive approaches have recently been evaluated (see below).
Parasite control in swine production – current status
Currently, antiparasitic treatment schemes for pigs is com-
prised of a “standard” application scheme for different pro-
duction branches; they are not “tailor-made” or risk-based
and not driven by diagnosis, since metaphylactic application
of antiparasitic drugs during the prepatent phase (when par-
asites cannot readily be detected by routine screening) is
preferred to prevent dissemination of environmental stages
(especially nematode eggs or coccidia oocysts) and infection
of the litter or herd. Complete elimination from a herd is
often difficult to achieve due to high prevalences, frequent
distribution and durable environmental stages, the best ex-
ample being eggs of A. suum which are almost impossible to
inactivate and which can remain infectious for years under
suitable conditions [27, 45]. An exception is the control of
mange; S. scabiei has no long-lived environmental stage and
relies on direct contact for transmission, so systematic appli-
cation of acaricides can effectively reduce infection and
stamping out the parasite on a farm is possible when quar-
antine measures and proper diagnostic screening are in
place (e.g. [38]). However, sustainability is jeopardized by the
development of acaricide resistance as reported from human
scabies [22]. Integrated measures like complete all-in-all-out
and disinfection with effective chemicals can relieve the in-
fection pressure of endoparasite infections [15] but eradica-
tion is generally considered not feasible. Although resistance
against anthelmintics in pig nematodes seems to be re-
stricted to Oesophagostomum at low frequencies [2, 9, 41]
and resistance to anticoccidials in the control of C. suis is
currently not reported, the limited number of substances
available especially for parasite control in pigs is of concern;
especially because no routine tests are available for the
detection of parasiticide resistance, and no programs to
delay the development of resistance (like shuttle programs
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as for chicken coccidiosis prevention [44] or equine cyathos-
tominosis) are in place. Alternative control strategies (for
review see [32]) haven been shown to be effective but are
currently not commercially available. It must therefore be
assumed that, although currently parasites may not be
considered as an issue of major concern in pig health and
production, in the long run alternatives to the current
chemotherapy must be sought to maintain appropriate
control and efficacy of available drugs.
Consequences of neonatal enteric infections: parasites
and their buddies
At the time of birth the porcine immune system is poorly
developed (for review see [47]); intestinal Peyer’s patches
contain almost no immune cells and the gut epithelium
and subepithelial tissues are only completely populated with
T- and B-cells and antigen-presenting cells at about six
weeks of age, leaving ample time for pathogens to establish
and reproduce. At the same time, the gut microbiota are
establishing and infections with pathogens at a very early
age may have a number of consequences beyond transient
parasite infection. Synergistic effects have been described
for C. suis and toxigenic Clostridium perfringens where
timely anticoccidial treatment also alleviated the effects of
clostridiosis [26], showing that C. suis infections promote
adhesion of clostridia to the intestinal mucosa, exacerbating
the effects of bacterial infection. Preliminary studies also
indicated that infections with C. suis alter the succession of
bacterial communities in neonatal pig gut, delaying the es-
tablishment of lactobacilli (as reviewed in [37]). As interac-
tions between microbiota and the immune system are key
to the development of a functional immune system [40]
such events may have lasting effects on the development of
intestinal and immune functions. As such alterations have
been described for other intestinal parasitic infections [21],
a role of intestinal parasitic infections in gut health should
be re-evaluated in pigs, too.
Cystoisospora suis - a candidate for vaccination?
As mentioned above, C. suis is an important cause of neo-
natal diarrhoea; infected animals excrete several million
oocysts in the patent phase of infection and the dissemin-
ation within and between litters accounts for a rapid spread
of the parasite with the consequence of transmission to the
majority of piglets within the first week after birth.
Although infections are transient with creamy to watery
non-haemorrhagic diarrhoea for one to six days, affected
animals often develop poorly and stay smaller even until
weaning compared to healthy (treated) litter mates [25],
which accounts for the financial losses attributed to this
disease [17, 33] requiring treatment. In addition, dysbiosis
may contribute to increased morbidity (see above) and
require antibiotic treatment [7]. Good control of oocyst
excretion and coccidiosis-related diarrhoea is achieved by
metaphylactic treatment of piglets on the third to fifth day
of life with a single dose of toltrazuril (20 mg/kg of body
weight) but recently questions about the sustainability of
“blanket treatment” of piglets in terms of resistance and
drug residues in meat have risen (see [37]), and a call for
alterative control strategies has been voiced.
C. suis as a member of the Apicomplexa, which have a
strictly intracellular development in the host, was assumed
to be under the control of the cellular immune system,
mainly NK cells, CD4+ and CD8+ T-cells, while antibodies
are probably not protective [47]. Phenotyping of cells after
primary infection revealed that several subpopulations of T-
cells (especially γδ-T cells and, TH cells) were decreased in
peripheral organs (blood, spleen) but increased in the
jejunum upon infection), and after challenge infection
(5 months after primary infection) these cell populations
also produced interferon-γ (which is crucial for the defence
against apicomplexan parasites) and were able to proliferate
upon antigen stimulation [8, 48, 49]. Thus, despite consider-
able individual reactions, it can be assumed that C. suis can
induce specific primary and adaptive immune reactions in
pigs including the induction of an immunological memory.
Since a relative of C. suis, Cryptosporidium parvum which
also inhabits the epithelium of the small intestine, is at least
partially controlled by specific antibodies [23], investigations
in the possible role of anti-C. suis antibodies were made and
colostral transfer of antibodies resulting in high serum levels
in piglets was described, and IgA levels in the blood of
piglets experimentally infected with C. suis soon after birth
were negatively correlated with diarrhoea [34]. When sows
were inoculated before birth with high doses of C. suis
oocysts, no clinical signs or oocyst excretion were noticed
but the levels of immunoglobulins (especially IgA) in their
blood, colostrum and milk were correlated with a decrease
in diarrhoea and oocyst excretion in their experimentally
infected off spring compared to piglets from non-
superinfected sows [35], indicating that application of oo-
cysts to sows ante partum can confer at least partial protec-
tion against C. suis in piglets. It was also concluded that the
role of the sow in spreading the parasite is probably minor
since even after infection with high doses (100,000 oocysts /
sow) no shedding was observed; however in the immunity
against C. suis the role of the mother in the provision of
colostrum containing protective substances is probably
pivotal. From this it is currently assumed that immuno-
logical control of neonatal porcine cystoisosporosis would
have to be conferred as a maternal vaccination which could
be applied in time before the infection of the new-born pig-
lets to immunologically mature gilts or sows and could be
boostered by natural infections circulating in a herd.
Determination of vaccine candidates – the way forward
Current vaccines against coccidian in chicken are mostly
virulent or attenuated live vaccines (see above). This
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technology requires the use of animals for production of
vaccines with all its disadvantages (biosafety, ethical
concerns etc.). Lately, a subunit vaccine against Eimeria
maxima of chicken was developed and marketed for use
in maternal immunization [36, 42]. Although it is also
produced in animals and its lasting success in the field still
remains to be evaluated, the concept of inactivated vaccines
against parasites has received a significant incentive with this
development. Until recently, the search for new vaccine
candidate molecules was slow and cumbersome due to the
lack of cost-effective high yield / high throughput in vitro
techniques for parasite propagation and screening. New
techniques in biotechnology and bioinformatics have
enabled rapid and cost-effective screening of genomes and
transcriptomes of parasites for vaccine and drug target can-
didates (as reviewed in [4, 12], and others) including A.
suum [13], T. suis [14], T. gondii (www.toxodb.org/) and C.
suis (Palmieri, submitted). For C. suis a genome size of 83
Megabases encoding >8300 genes is estimated, and a re-
cently developed pipeline for the search of vaccine candi-
dates in apicomplexan parasites (Vacceed; [10]) has detected
562 candidates in C. suis which now need to be evaluated
further in silico, in vitro (using a cell culture system support-
ing the complete life cycle of C. suis; [50]) and in vivo.
Conclusion
In summary, although vaccines against porcine parasites
do not seem to be an immediate issue for pig industry
and health, the time to get started has never been better,
as new tools and technologies are greatly accelerating
the achievements in this field of veterinary medicine.
C. suis would be an attractive candidate for vaccine de-
velopment, as preliminary data have shown that a protect-
ive effect could be achieved by immunisation of sows;
however, more basic and applied research will be needed to
fully understand the mechanisms that lead to protection.
Joint forces of the veterinary profession, immunology,
bioinformatics and biotechnology specialists will be re-
quired to develop and test new vaccine concepts and vac-
cines to be suitable for a competitive market. Combinations
of vaccines and optimised delivery systems will have to be
developed alongside to incorporate anti-parasite vaccines
into the health management systems of pig production.
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